Eagle's Eye View: Your Weekly CV Update From ACC.org

Cardiologists Dharam Kumbhani, Ki Park, and Ajay Kirtane discuss the results of the pooled analysis of the radiant trials, showing that renal denervation can significantly reduce blood pressure. They also explore the potential approval of renal denervation in the US and present a quality of life analysis of tricuspid transcatheter edge-to-edge repair.

In this week’s View, Dr. Eagle explores a UK Biobank study on triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease. He then discusses the risk of atrial and ventricular arrhythmia comparing carvedilol versus metoprolol among implantable cardioverter defibrillator recipients. Finally, Dr. Eagle examines the results from the ORION-5 randomized clinical trial that looked at the efficacy, safety, and tolerability of inclisiran in patients with homozygous familial hypercholesterolemia.   Subscribe to Eagle’s Eye View  

Drs. Dharam Kumbhani, Ki Park, and Ajay Kirtane review the late-breaking clinical trials from Wednesday, Oct. 25 at TCT 2023, including AGENT IDE (0:45), T-PASS (3:44), and SWEDEHEART (6:50).  For trial summaries, news coverage, daily video wrap-ups and more, visit ACC's Meeting Coverage Page (linked here) Follow the ACC on Social Media (linked here) and use the hashtag #TCT2023.  (https://twitter.com/hashtag/TCT2023).    Subscribe to Eagle’s Eye View  

Drs. Dharam Kumbhani, Ki Park, and Ajay Kirtane review the late-breaking clinical trials from Tuesday Oct. 24 at TCT 2023 including PARTNER 3 (0:45) and Evolut (4:36). The ACC is providing coverage of the lates-breaking clinical science being presented at TCT 2023 in San Francisco. For trial summaries, news coverage, daily video wrap-ups and more, visit ACC's Meeting Coverage Page (linked here) Follow the ACC on Social Media (linked here) and use the hashtag #TCT23 (https://twitter.com/hashtag/TCT23).    Subscribe to Eagle’s Eye View  

In this special edition of the View, Dr. Eagle summarizes the top science that will be presented at TCT 2023 from October 23rd to October 26th in San Francisco.   Dr. Eagle shares some of the trials that have captured attention, including: Four Year Outcomes from the EVOLUT Low Risk Trial, Five-Year Clinical and Echocardiographic Outcomes from the PARTNER 3 Low Risk Randomized Trial, Less-Than One-Month Dual Antiplatelet Therapy Followed by Ticagrelor Monotherapy After Coronary Drug Eluting Stent Implantation for Acute Coronary Syndrome, TRISCEND II: A Randomized Trial of Transcatheter Tricuspid Valve Replacement, and Individual Patient Data Pooled Analysis of Endovascular Ultrasound Renal Denervation.   These trials hold significant promise for advancing the field of interventional cardiology, of Eagle’s Eye View looks forward to reviewing the results at TCT 2023.    There will be daily updates giving more details on these trials and more.   Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle explores the role of one- or three-month DAPT in HBR patients with or without oral anticoagulant therapy after PCI. He then discusses a meta-analysis of the co-administration of mineralocorticoid receptor antagonists with sodium–glucose co-transporter-2 inhibitors in heart failure. Finally, Dr. Eagle examines the use of PET imaging in following patients with giant cell arteritis.   Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle explores the efficacy of pulmonary artery pressure monitoring in patients with chronic heart failure. He then discusses the performance of the ACC/AHA Pooled Cohort Cardiovascular Risk Equations in clinical practice. Finally, Dr. Eagle examines JACC’s State-of-the-Art Review of antithrombotic therapy for primary and secondary prevention of ischemic stroke.   Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle explores the benefits and drawbacks of vegetarian and vegan diets. He then discusses LDL cholesterol reduction for primary prevention of major vascular events in the elderly. Finally, Dr. Eagle examines the lack of association between fluoroquinolone and aortic aneurysm or dissection.   Subscribe to Eagle’s Eye View